Wolowacz SE, Petrillo J, Doward LC, Briggs A. Measuring health-state utility values in clinical trials: can we do better? Ispor Connections. 2014 Sep;20(5):4-8.
Stull DE, Houghton KF, Petrillo J. Innovative data analysis for demonstrating product value: analysis of heterogeneity in treatment response in clinical trials. Ispor Connections. 2013;19(1):5-8.
Masters E, Zlateva G, Harris NI. Real-world data for use in the real world: the pain paradigm. Ispor Connections. 2013;19(2):9-11.
Dalal AA, Shaw MB, D'Souza AO, Lunacsek OE, Nagar SP, Crater GD. Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD. Resp Res. 2012 May;31(13):41.
Smit LA, Kogevinas M, Anto JM, Bouzigon E, Gonzalez JR, Le Moual N, Kromhout H, Carsin AE, Pin I, Jarvis D, Vermeulen R, Janson C, Heinrich J, Gut I, Lathrop M, Valverde MA, Demenais F, Kauffmann F. Transient receptor potential genes, smoking, occupational exposures and cough in adults. Resp Res. 2012 Mar 23;13(1):26. doi: 10.1186/1465-9921-13-26
Wolowacz SE, Khan SB. The New National Institute of Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process: experience from the first completed appraisals. Ispor Connections. 2007;13(2):12-5.
Westfall PH, Prillaman B, Ho SY. Properties of multiple intersection-union tests for multiple endpoints in combination therapy trials. J Biopharm Stat. 2001;11(3):125-38. doi: 10.1081/BIP-100107653